Skip to main content

Table 6 Association between cardiovascular comorbidities and use of biologicals, in particular those of the anti-TNF class

From: Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study

  Biologicals Anti-TNF
Yes n*(%) PRˆ (IC95%) p Yes n*(%) PRˆ (IC95%) p
Cardiovascular Comorbidities Yes 276 (69.3) 1.147 (1.050–1.253) 0.003 148 (66.7) 1.060 (0.954–1.179) 0.292
No 122 (30.7) 0.775 (0.652–0.922) 74 (33.3) 0.898 (0.731–1.101)
Systemic Arterial Hypertension Yes 219 (55) 1.169 (1.039–1.315) 0.011 116 (52.3) 1.059 (0.919–1.221) 0.436
No 179 (45) 0.850 (0.747–0.967) 106 (47.7) 0.942 (0.808–1.097)
Dyslipidemia Yes 144 (36.2) 1.186 (1.000–1.407) 0.052 80 (36) 1.138 (0.932–1.390) 0.212
No 254 (63.8) 0.918 (0.841–1.003) 142 (64) 0.936 (0.840–1.043)
Diabetes Mellitus Yes 65 (16.3) 1.161 (0.872–1.546) 0.308 31 (14) 0.925 (0.644–1.328) 0.670
No 333 (83.7) 0.974 (0.924–1.020) 191 (86) 1.013 (0.955–1.076)
Congestive Heart Failure Yes 10 (2.5) 1.289 (0.578–2.874) 0.535 3 (1.4) 0.575 (0.173–1.911) 0.448
No 388 (97.5) 0.994 (0.976–1.013) 219 (98.6) 1.010 (0.992–1.029)
Cerebrovascular Disease Yes 4 (1) 0.361 (0.124–1.048) 0.054 1 (0.5) 0.175 (0.024–1.289) 0.066
No 394 (99) 1.018 (1.002–1.035) 222 (99.5) 1.022 (1.008–1.036)
Acute Myocardial Infarction Yes 12 (3) 4.330 (1.536–12.201) 0.002 3 (1.4) 0.863 (0.250–2.977) 1.000
No 386 (97) 0.977 (0.959–0.995) 219 (98.6) 1.002 (0.985–1.020)
Peripheral Vascular Disease Yes 3 (0.8) 1.082 (0.260–4.505) 1.000 1 (0.5) 0.575 (0.071–4.652) 1.000
No 395 (99.2) 0.999 (0.989–1.010) 221 (99.5) 1.003 (0.993–1.014)
  1. *Absolute frequencies; ˆ Prevalence Ratio Significance level